Guggenheim Starts Assembly Biosciences (ASMB) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ASMB Hot Sheet
Price: $19.87 --0%
Rating Summary:
8 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 26 | New: 2
Rating Summary:
8 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 26 | New: 2
Join SI Premium – FREE
Guggenheim analyst Vamil Divan initiates coverage on Assembly Biosciences (NASDAQ: ASMB) with a Buy rating and a price target of $31.00.
For an analyst ratings summary and ratings history on Assembly Biosciences click here. For more ratings news on Assembly Biosciences click here.
Shares of Assembly Biosciences closed at $11.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Double Downgrades LegalZoom.com Inc (LZ) to Underperform
- Goldman Sachs Downgrades Regis Resources Ltd. (RRL:AU) (RGRNF) to Sell
- Needham Reiterates Buy Rating on Clover Health (CLOV)
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Guggenheim, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
